IV form of osteoporosis treatment approved
GlaxoSmithKline and Roche have received FDA approval for Boniva (ibandronate sodium) injection, the first intravenous treatment for postmenopausal osteoporosis. The drug provides an alternative for patients who cannot take an oral medication or are unable to remain upright for 30 to 60 minutes, a requirement when taking the tablet form of bisphosphonates. Ibandronate injection should be administered by a healthcare professional once every three months and will be available early this year.
Recent Videos
Related Content
